KG&L Capital Management LLC lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,267 shares of the company’s stock after selling 1,840 shares during the quarter. Johnson & Johnson accounts for 2.4% of KG&L Capital Management LLC’s portfolio, making the stock its 11th largest position. KG&L Capital Management LLC’s holdings in Johnson & Johnson were worth $5,010,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Atlantic Private Wealth LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth about $32,000. Ruedi Wealth Management Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth about $42,000. 25 LLC purchased a new position in Johnson & Johnson in the 1st quarter worth about $55,000. Horizons Wealth Management increased its stake in Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock worth $61,000 after buying an additional 346 shares during the period. Finally, Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth about $66,000. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Stock Up 0.3 %
Shares of Johnson & Johnson stock opened at $157.60 on Friday. The firm’s 50 day moving average price is $164.30 and its 200-day moving average price is $162.27. The company has a market cap of $409.60 billion, a P/E ratio of 31.90, a PEG ratio of 3.14 and a beta of 0.55. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Insider Buying and Selling
In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Royal Bank of Canada assumed coverage on shares of Johnson & Johnson in a research note on Wednesday. They issued an “outperform” rating and a $178.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Atlantic Securities raised their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Barclays cut their target price on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research report on Friday, September 8th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $171.06.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
- Roth IRA Calculator: Calculate Your Potential Returns
- Starbucks Is About To Become A Value Play You Can’t Miss
- How to Start Investing in Penny Stocks
- Intel to Unlock Value By Spinning Off Programmable Chip Unit
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
